MedTrace Logo

RC48-ADC in HER2-low Advanced Breast Cancer

NCT05831878 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2026-05-13

No results posted yet for this study

Summary

To evaluate the efficacy and safety of Disitamab vedotin (RC48-ADC) as salvage treatment in patients with HER2-low advanced breast cancer who have received up to one previous chemotherapy for recurrent or metastatic disease without previous use of antibody-drug conjugate.

Conditions

Interventions

DRUG

Disitamab vedotin

2.0mg/kg, iv, day1, every 2 weeks

Sponsors & Collaborators

  • RenJi Hospital

    lead OTHER

Principal Investigators

  • Wenjin Yin, M.D. · Renji Hospital,School of Medicine, Shanghai Jiaotong University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-04
Primary Completion
2026-12-31
Completion
2027-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05831878 on ClinicalTrials.gov